THÔNG TIN TÀI LIỆU
Thông tin cơ bản
| Tiêu đề | Clinical manifestations of pulmonary tuberculosis pot |
|---|---|
| Tác giả | Nesli Basgoz, MD |
| Người hướng dẫn | C Fordham von Reyn, MD |
| Trường học | Harvard Medical School |
| Chuyên ngành | Medicine |
| Thể loại | lecture notes |
| Năm xuất bản | 2010 |
| Thành phố | Cambridge |
| Định dạng | |
|---|---|
| Số trang | 131 |
| Dung lượng | 553,58 KB |
Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này
Nội dung
Ngày đăng: 29/03/2014, 03:20
Nguồn tham khảo
| Tài liệu tham khảo | Loại | Chi tiết | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 4. Kaplan, JE, Benson, C, Holmes, KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1 | Sách, tạp chí |
|
||||||||
| 7. CDC. Managing Drug Interactiosn in the treatment of HIV related tuberculosis 2007. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm | Sách, tạp chí |
|
||||||||
| 18. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. Available from URL:http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on June 7, 2010) | Sách, tạp chí |
|
||||||||
| 24. Manosuthi, W, Sungkanuparph, S, Tantanathip, P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752 | Sách, tạp chí |
|
||||||||
| 33. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 12 weeks efficacy of nevirapine, 400 mg vs. 600 mg per day in HIV-infected patients with active TB receiving rifampicin: a multicenter study. Presented at the 14thConference on Retroviruses and Opportunistic Infections; February 25-28, 2007;Los Angeles, CA | Sách, tạp chí |
|
||||||||
| 34. Swaminathan, S, Padmapriyadarsini, C, and Venkatesan, P, et al. Once-daily nevirapine versus efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 35 | Sách, tạp chí |
|
||||||||
| 40. Wenning, LA, Hanley, WD, Brainard, DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.Antimicrob Agents Chemother 2009; 53:2852 | Sách, tạp chí |
|
||||||||
| 41. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. Available from URL:http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on August 24, 2009) | Link | |||||||||
| 1. Havlir, D. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423 | Khác | |||||||||
| 2. Onyebujoh, PC, Ribeiro, I, Whalen, CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis 2007; 196 Suppl 1:S35 | Khác | |||||||||
| 3. Blumberg, HM, Burman, WJ, Chaisson, RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603 | Khác | |||||||||
| 5. Mitchison, D. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796 | Khác | |||||||||
| 8. Murray, J, Sonnenberg, P, Shearer, SC, Godfrey-Fausett, P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999;159:733 | Khác | |||||||||
| 9. Sterling, TR, Alwood, K, Gachuhi, R, et al. Relapse rates after short-course (6- month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899 | Khác | |||||||||
| 10. Breen, RA, Miller, RF, Gorsuch, T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006;193:1437 | Khác | |||||||||
| 11. Vernon, A, Burman, W, Benator, D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843 | Khác | |||||||||
| 12. Swaminathan, S, Narendran, G, Venkatesan, P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis:a randomized clinical trial. Am J Respir Crit Care Med 2010; 181:743 | Khác | |||||||||
| 13. Nettles, RE, Mazo, D, Alwood, K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731 | Khác | |||||||||
| 14. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214 | Khác | |||||||||
| 15. Burman, W, Benator, D, Vernon, A, et al. Acquired rifamycin resistance with twice- weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173:350 | Khác |
TỪ KHÓA LIÊN QUAN
TÀI LIỆU CÙNG NGƯỜI DÙNG
TÀI LIỆU LIÊN QUAN
🧩 Sản phẩm bạn có thể quan tâm